Docetaxel (Taxotere®) in the neo-adjuvant setting in non-small-cell lung cancer

Docetaxel in non-small cell lung cancer

Taxotere: Clinical Trials in Non-Small Cell Lung Cancer.

Cisplatin-based chemotherapy regimens of the 1980s have shown a small but significant impact on survival for patients with advanced non-small cell lung cancer (NSCLC). New agents, including docetaxel, have shown encouraging single-agent activity in this disease. This potent microtubule stabilizing agent was selected for clinical development based on its preclinical superiority to paclitaxel. Th...

Docetaxel/Vinorelbine Combination Therapy in Non-Small-Cell Lung Cancer

Docetaxel (Taxotere) and vinorelbine (Navelbine) are two of a number of new third-generation chemotherapeutic agents that have become available in recent years. A series of single-agent and combination therapy studies are underway to determine the efficacy of these agents in the treatment of patients with non-small-cell lung cancer. Although docetaxel and vinorelbine are considered tubulin-bind...

Individualized therapy in the adjuvant setting for non-small cell lung cancer (NSCLC)

Based on meta-analyses and the results of several trials, adjuvant chemotherapy is currently recommended for stage II and stage III non-small cell lung cancer (NSCLC) patients after complete tumor resection, and may be considered for patients with stage IB NSCLC ≥ 4 cm. As individualized therapy becomes integrated into the care of advanced NSCLC, its role in early stage NSCLC and, in particular...

Sentinel Node Mapping in Non-small Cell Lung Cancer Using an Intraoperative Radiotracer Technique

 Objective(s): Lymph node metastases are the most significant prognostic factor in localized non-small cell lung cancer (NSCLC). Identification of the first nodal drainage site (sentinel node) may improve detection of metastatic nodes. Extended surgeries, such as lobectomy or pneumonectomy with lymph node dissection, are among the therapeutic options of higher acceptab...